Company Overview
About Epinoma
Epinoma is a San Francisco-based biotech company engineering proteins that read and write epigenetic signals — developing protein tools for earlier cancer and disease detection through liquid biopsy (blood tests that detect disease-specific epigenetic marks) and therapeutic interventions that modify epigenetic states to treat disease without permanently altering DNA sequence. A Y Combinator S21 graduate backed by George Church (Harvard genetics pioneer), seedToB, and SeaX Ventures with $125,000 raised, Epinoma achieved $1 million in revenue in 2024 with an 8-person team, targeting the $50 billion blood test development market.
Business Model & Competitive Advantage
Epinoma's protein engineering platform designs novel proteins that can read specific epigenetic modifications (DNA methylation patterns, histone modifications) and write new epigenetic states at targeted genomic locations. Epigenetic marks — chemical modifications on DNA and histones that regulate gene expression without changing DNA sequence — are increasingly recognized as disease biomarkers and therapeutic targets. For liquid biopsy diagnostics, specific methylation patterns in circulating tumor DNA can indicate cancer type and stage earlier than traditional biomarkers. For therapeutics, epigenetic editing can silence oncogenes or activate tumor suppressor genes.
Competitive Landscape 2025–2026
In 2025, Epinoma competes in the epigenomics tools and liquid biopsy diagnostics market with Illumina (ILMN, sequencing instruments), Grail (Galleri multi-cancer early detection test), Exact Sciences (Oncotype), and epigenetic therapeutics companies including Constellation Pharmaceuticals (acquired by MorphoSys/Novartis) for epigenetic diagnostics and tools. The liquid biopsy market is rapidly growing as multi-cancer early detection (MCED) tests demonstrate clinical validity — Grail's Galleri test and similar platforms are generating significant commercial adoption. Epinoma's protein engineering approach to epigenetic tools could provide both better detection biomarkers and the therapeutic editing tools that convert diagnostic findings into treatment interventions. George Church's advisory role connects Epinoma to the Harvard synthetic biology ecosystem. The 2025 strategy focuses on commercializing the protein tools for research and diagnostic applications, building partnerships with diagnostics companies developing liquid biopsy assays, and advancing the epigenetic therapeutics platform toward clinical validation.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Epinoma is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Epinoma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Epinoma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Epinoma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Epinoma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →